Vianney Tuloup
Overview
Explore the profile of Vianney Tuloup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Royere A, Pourrat X, Le Nail L, Lartigue M, Lemaignen A, Tuloup V, et al.
Infect Dis Now
. 2024 Jul;
54(7):104958.
PMID: 39069005
Introduction: Management of bone and joint infections (BJI) requires prolonged and high-dose antibiotic therapy to achieve target concentrations in bone tissue. However, these therapies often lead to adverse effects in...
2.
Tuloup V, Millet A, Taricco A, Parant F, Ferry T, Goutelle S
Ther Drug Monit
. 2023 Feb;
45(4):562-565.
PMID: 36728573
Purpose: Increasing evidence supports daptomycin therapeutic drug monitoring. The author's reference center used to perform therapeutic drug monitoring in patients who receive high-dose daptomycin for bone and joint infections, with...
3.
Tuloup V, Goutelle S, Tod M, Bourguignon L
Clin Pharmacokinet
. 2023 Jan;
62(2):307-319.
PMID: 36631686
Background And Objective: Chronic kidney disease (CKD) may alter drug renal elimination but is also known for interacting with hepatic metabolism via multiple uremic components. However, few global models, considering...
4.
Reverchon J, Tuloup V, Garreau R, Nave V, Cohen S, Reix P, et al.
Pharmaceutics
. 2022 Aug;
14(8).
PMID: 36015375
Therapeutic drug monitoring (TDM) of tobramycin is widely performed in patients with cystic fibrosis (CF), but little is known about the value of model-informed precision dosing (MIPD) in this setting....
5.
Tuloup V, France M, Garreau R, Bleyzac N, Bourguignon L, Tod M, et al.
Antimicrob Agents Chemother
. 2021 Jul;
65(9):e0104321.
PMID: 34228545
Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude...